表紙
市場調查報告書

全球德國麻疹診斷檢驗市場:成長,趨勢,預測

Rubella Diagnostic Testing Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 850329
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球德國麻疹診斷檢驗市場:成長,趨勢,預測 Rubella Diagnostic Testing Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 113 Pages
簡介

本報告提供全球德國麻疹診斷檢驗市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 促進要素
    • 德國麻疹病毒削減的政府配合措施
    • 德國麻疹的發病數量的增加
    • 照護現場診斷技術的進步
  • 阻礙要素
    • 發展中國家的認識不足
  • 波特五力分析

第5章 市場區隔

  • 檢驗各技術
    • 乳膠凝集測試
    • 酵素免疫分析法(EIA)
    • 無線電免疫測量(RIA)
    • 螢光免疫分析法
    • 其他
  • 各用途
    • 醫院
    • 實驗室
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Abbott
    • Beckman Coulter Inc.
    • Bio Rad Laboratories Inc.
    • Biokit SA
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd
    • Ortho Clinical Diagnostics
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific
    • ZEUS Scientific Inc.

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 66028

Market Overview

The major factors for the growth of the rubella diagnostic testing market include the government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies, which are expected to boost the overall growth of the market over the forecast period.

There has been an increase in the number of incidences of rubella across the world. Rubella is an acute, contagious viral infection that causes a mild fever and rash illness in children and adults. Infection during pregnancy, especially during the first trimester, can result in miscarriage, stillbirth, fetal death, or infants with congenital malformations. According to the data published by the Centers for Disease Control and Prevention (CDC), rubella is a global health concern, and every year, more than 100,000 cases of congenital rubella syndrome (CRS) are reported, globally. A woman infected with rubella during the first three months of pregnancy has up to a 90% chance of giving birth to a baby with congenital rubella syndrome.

In 2015, the WHO Region of the Americas became the first in the world to be declared free of endemic transmission of rubella. Rubella can be prevented with the measles, mumps, and rubella (MMR) vaccine. Governments in various countries across the world are conducting vaccination programs to curb the incidences of rubella. As per the estimates of WHO, as of December 2016, 152 out of 194 countries had introduced rubella vaccines and reported rubella cases declined by 97%, from 670,894 cases in 102 countries, in 2000, to 22,361 cases in 165 countries in 2016.

On the other hand, as per the Global Vaccine Action Plan (GVAP) Assessment report, rubella control is lagging, with 42 countries yet to introduce the vaccine.

Scope of the Report

As per the scope of the report, rubella diagnostic testing refers to the detection of the rubella virus. These tests are prescribed for pregnant women and may also be performed on babies born with congenital defects. Rubella can be detected with the help of various diagnostic tests, such as latex agglutination, enzyme immunoassay, radioimmunoassay (RIA), and fluorescent immunoassay (FIA), among others.

Key Market Trends

Enzyme Immunoassay Segment under Testing Technique Accounted for the Largest Share in the Global Market

The detection of rubella-specific immunoglobulin M (IgM) in serum is the standard test for the rapid laboratory diagnosis of rubella. IgM testing is the most commonly performed testing technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies that are made by the immune system to kill the rubella virus, and these antibodies remain in the bloodstream for years. The segment is expected to account for the largest market share, owing to the rising incidences of rubella.

Asia-Pacific Accounted for the Highest Growth Rate in the Global Market

The Asia-Pacific segment, by geography, was found to register the fastest growth rate for the rubella diagnostic testing market and is expected to show a similar trend over the forecast period, without significant fluctuations. The Asia-Pacific region holds the highest market share, owing to the presence of larger untapped opportunities, a lack of awareness in some countries, and government initiatives to curb the disease incidence. As per the Global Vaccine Action Plan (GVAP) Assessment report 2017, 42 countries have not yet introduced the vaccine, and two regions, Africa and the Eastern Mediterranean, have not yet set rubella elimination or control targets. Such regions are expected to face high incidences of rubella, which may further drive the growth of the market.

Competitive Landscape

The market studied is dominated by a few major players and most of the players present in the market are focusing on the development of new technologies to acquire the maximum market share. The presence of major market players, such as Abbott Laboratories, Bio Rad Laboratories Inc., BioMerieux SA, Siemens AG, and Thermo Fisher Scientific Inc., is increasing the overall competitive rivalry in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Government Initiatives to Curb Rubella Virus
    • 4.2.2 Increasing Incidences of Rubella
    • 4.2.3 Introduction of Advance Point-of-care Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness among Developing Regions
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Testing Technique
    • 5.1.1 Latex Agglutination
    • 5.1.2 Enzyme Immunoassay (EIA)
    • 5.1.3 Radioimmunoassay (RIA)
    • 5.1.4 Fluorescent Immunoassay (FIA)
    • 5.1.5 Other Testing Techniques
  • 5.2 Application
    • 5.2.1 Hospitals
    • 5.2.2 Laboratories
    • 5.2.3 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Beckman Coulter Inc.
    • 6.1.3 Bio Rad Laboratories Inc.
    • 6.1.4 Biokit SA
    • 6.1.5 bioMerieux SA
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Ortho Clinical Diagnostics
    • 6.1.8 Siemens Healthcare GmbH
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 ZEUS Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top